Trailhead Biosystems
Beachwood, US · Delaware corporation · 1 known investors
Trailhead Biosystems develops HD-DoE (High-Dimensional Design-of-Experiments), a platform that uses computational models and control systems to differentiate human induced pluripotent stem cells (iPSCs) into specific cell types for regenerative medicine and stem cell research. The company serves stem cell researchers and cell-therapy developers with iPSC research products and differentiation technologies.
Founders & leadership
JJ
Jan JenseninFounder
JS
Joshua SnowChief Commercial Officer
DT
Divya TrivediChief Operating Officer and Secretary
DL
David LlewellynPresident & CEO
JS
Josh SnowinChief Commercial Officer
JA
Jennifer AntonchukinVice President of Research and Development
Board
MK
Michael KaufmanBoard director
CN
Craig NemiroffBoard director
WH
Wolfgang HofmannBoard director
HH
Houman HemmatiBoard director
MP
Magnus PerssonChairman
Investors · 1
Reported raises · per SEC filings
Form D private placements$62.3M disclosed across 5 rounds · 2020–2024
▶$40.6MraisedJul 2026 · 7 investors · BiotechnologyRule 506(b)
▶$40.6MraisedJul 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David LlewellynExecutive Officer, Director
- Craig NemiroffDirector
- Joshua SnowExecutive Officer
- Wolfgang HofmannDirector
- Houman HemmatiDirector
- Divya TrivediExecutive Officer
- Michael KaufmanExecutive Officer, Director
- Jan JensenDirector
- Offering amount
- $40.6M
- Amount sold
- $40.6M
- Minimum investment
- $50K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$3MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Divya TrivediExecutive Officer
- Magnus PerssonDirector
- Michael KaufmanDirector
- Houman HemmatiDirector
- Jan JensenExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- Minimum investment
- $25K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedSep 2022 · 6 investors · BiotechnologyRule 506(b)
▶$10MraisedSep 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Divya TrivediExecutive Officer
- Magnus PerssonDirector
- Houman HemmatiDirector
- Jan JensenExecutive Officer, Director
- Michael KaufmanDirector
- Offering amount
- $10.1M
- Amount sold
- $10M
- Minimum investment
- $25K
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.6MraisedOct 2021 · 13 investors · BiotechnologyRule 506(b)
▶$8.6MraisedOct 2021 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael A. KaufmanDirector
- Jan JensenExecutive Officer, Director
- Div TrivediExecutive Officer
- Magnus PerssonDirector
- Houman HemmatiDirector
- Offering amount
- $8.6M
- Amount sold
- $8.6M
- Minimum investment
- $25K
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedJun 2020 · 3 investors · BiotechnologyRule 506(b)
▶$100KraisedJun 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Div TrivediExecutive Officer
- Magnus PerssonDirector
- Jan JensenExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $100K
- Minimum investment
- $25K
- Proceeds to insiders
- $100K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Vedantu100 shared keywordsVedantu is an online learning platform that provides free chapter-wise NCERT solutions and study materials for Class 12 CBSE students across Science, Commerce, and Arts subjects. It also offers resources for competitive exam preparation such as JEE and NEET, aligned with the latest CBSE syllabus.
Osmosis77 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
Companies competing with Trailhead Biosystems for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $146.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Trailhead Biosystems do?
- Trailhead Biosystems develops HD-DoE (High-Dimensional Design-of-Experiments), a platform that uses computational models and control systems to differentiate human induced pluripotent stem cells (iPSCs) into specific cell types for regenerative medicine and stem cell research. The company serves stem cell researchers and cell-therapy developers with iPSC research products and differentiation technologies.
- Who founded Trailhead Biosystems?
- Trailhead Biosystems was founded by Jan Jensen.
- Who are Trailhead Biosystems's investors?
- Trailhead Biosystems's investors include CWRU Technology Ventures.
- How much funding has Trailhead Biosystems raised?
- Trailhead Biosystems has disclosed $62.3M raised across 5 rounds.
- Where is Trailhead Biosystems headquartered?
- Trailhead Biosystems is headquartered in Beachwood, US.